Abstracts tagged "Pediatric rheumatology"

Abstract Number: 1300 • ACR Convergence 2025
International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
Chandni Sarker¹, Jennifer Cooper², Emily Smitherman³, Flavia Alves¹, Alexandre Belot⁴, Michael Beresford⁵, Andreea Jorgensen¹, Eve Smith⁶, Laura Lewandowski⁷ and Rebecca Sadun⁸, ¹University of Liverpool, Liverpool, United Kingdom, ²University of Colorado/Children's Hospital Colorado, Aurora, CO, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Hospices Civils de Lyon, Collonges au mont d'or, France, ⁵Alder Hey Children's NHS Foundation Trust Hospital, Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷NIAMS, NIH, Bethesda, MD, ⁸Duke University, Durham, NC
Background/Purpose: Consensus-derived treat-to-target (T2T) goals for childhood-onset SLE (cSLE), including clinical remission on low dose steroids (cCR), have been endorsed by the Paediatric Rheumatology European…
Abstract Number: 1283 • ACR Convergence 2025
Impact of Guideline Concordant Care of Renal Outcomes in Childhood-Onset Lupus Nephritis
Alisha Akinsete¹, Orysya Soroka², Mangala Rajan², Karen Onel³, Monika Safford² and Iris Navarro-Millan⁴, ¹Weill Cornell Medical Center, New York, NY, ²Weill Cornell Medicine, New York, ³HSS, New York, NY, ⁴Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY
Background/Purpose: End-stage renal disease (ESRD) is a serious complication of lupus nephritis (LN), yet the effect of guideline-concordant care on this outcome is unclear. Despite…
Abstract Number: 0875 • ACR Convergence 2025
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
Lawrence Eichenfield¹, Ricardo Galimberti², Adelaide Hebert³, Wen-Hui Wang⁴, Jennifer Soung⁵, Nina Magnolo⁶, John Browning⁷, Angela Moore⁸, Mark Lebwohl⁹, Dagmar Wilsmann-Theis¹⁰, Joseph F Merola¹¹, Georgios Kokolakis¹², Dariusch Mortazawi¹³, Parbeer Grewal¹⁴, Megan Miller¹⁵, Joseph Cafone¹⁶, Shu Li¹⁷, Gigi Jiang¹⁷, Fabio Nunes¹⁷, Cynthia DeKlotz¹⁸ and Amy Paller¹⁹, ¹University of California, San Diego School of Medicine, La Jolla, CA, USA, La Jolla, CA, ²Hosp Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ³University of Texas Medical School-Houston, Bellaire, TX, USA, Bellaire, TX, ⁴Peking University Third Hospital, Haidian District, Beijing, China, Beijing, China (People's Republic), ⁵Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁶University Hospital Muenster, Muenster, Germany, Muenster, Germany, ⁷Methodist Children's Hospital, San Antonio, TX, USA, San Antonio, TX, ⁸Baylor University Medical Center, Dallas, TX, USA, Dallas, TX, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰University Hospital Bonn, Center for Skin Diseases, Bonn, Germany, Bonn, Germany, ¹¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ¹²Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ¹³Clinical Research Center, Remscheid, Germany, Remscheid, Germany, ¹⁴University of Alberta, Edmonton, Alberta, Canada, Edmonton, AB, Canada, ¹⁵Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ¹⁶Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ¹⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹⁸Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Chicago, IL
Background/Purpose: Icotrokinra (ICO), a novel targeted oral peptide, binds the interleukin (IL)-23 receptor to inhibit IL-23 signaling. ICONIC-LEAD (NCT06095115) is the first Phase 3 study…
Abstract Number: 0407 • ACR Convergence 2025
The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort
Ilaria Maccora¹, Margaret Chang², Sheila Angeles-Han³, Andrea Taddio⁴, Lampros Fotis⁵, Cinzia de Libero⁶, Madison Mangin⁷, Alexandra Duell⁸, Marco Gabrielli⁹, Kyveli Chiotopoulou⁵, Lillian Sutton¹⁰, Virginia Miraldi Utz⁸ and Gabriele Simonini¹¹, ¹Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, ²Boston Children's Hospital, Boston, MA, ³Cincinnati Children's Hospital, Cincinnati, OH, ⁴Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, ⁵Division of Pediatric Rheumatology, Department of Pediatrics, ATTIKON General Hospital, National and Kapodistrian University of Athens, Greece, Athene, Greece, ⁶Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, Florence, Italy, ⁷Boston Children's Hospital, St Simons Island, GA, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹University of Trieste, Trieste, Italy, Trieste, Italy, ¹⁰Division of Immunology, Boston Children’s Hospital, Boston, MA, USA, Boston, ¹¹Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy
Background/Purpose: Childhood chronic non-infectious uveitis (cNIU) is a sight-threatening condition that can lead to blindness if not appropriately treated. cNIU is typically associated with Juvenile…
Abstract Number: 0302 • ACR Convergence 2025
Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM
Shannon O'Connor¹, Hermine Brunner¹, Josh Gunn², Payam Farhadi³, Carley Phillips⁴, Lisa Rider⁵, Alexei Grom¹ and Sheila Angeles-Han⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Ethos R&D, Newport, KY, ³National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune vasculopathy affecting muscle, skin, and vasculature. Core set measures (CSM) assess disease activity and damage, and guide treatment.…
Abstract Number: 2680 • ACR Convergence 2025
High Health Care Utilization Preceding Diagnosis of Juvenile Idiopathic Arthritis
Anna Costello¹, Rui Xiao¹, Jahan Jazayeri¹, Timothy Brandon¹, Xuemei Zhang¹, Irit Rasooly¹ and Pamela Weiss², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Timely diagnosis of Juvenile Idiopathic Arthritis (JIA) enables early initiation of therapy and improves outcomes, yet JIA patients often experience circuitous pathways to diagnosis.…
Abstract Number: 2165 • ACR Convergence 2025
Targeted Needs Assessment of Provider Medical Knowledge of Juvenile Scleroderma, a Mixed Methods Study
Rachel Guess¹, Megan Curran², Lisa Zickuhr³ and Rachel Moquin¹, ¹Washington University School of Medicine, St. Louis, MO, ²University of Colorado | Children's Hospital Colorado, Aurora, CO, ³Washington University/B-JH/SLCH Consortium, St. Louis, MO
Background/Purpose: Juvenile scleroderma (JS) is an autoimmune disease that can cause skin sclerosis leading to deformity, disability, and early mortality especially with delayed diagnosis. A…
Abstract Number: 2139 • ACR Convergence 2025
Real-Life Treatment Strategies for Refractory Still’s Disease: Results from a Worldwide Survey, the METAPHOR Project
Greta Rogani¹, Francesco Baldo², Claudia Bracaglia³, Dirk Foell⁴, Marco Gattorno⁵, Marija Jelusic⁶, Jordi Anton⁷, Paul Brogan⁸, Scott Canna⁹, Randy Cron¹⁰, Fabrizio De Benedetti¹¹, Alexei Grom¹², Merav Heshin Bekenstein¹³, AnnaCarin Horne¹⁴, Raju Khubchandani¹⁵, Mao Mizuta¹⁶, Seza Özen¹⁷, Pierre Quartier Dit Maire¹⁸, Angelo Ravelli¹⁹, Masaki Shimizu²⁰, Grant Schulert¹², Christiaan Scott²¹, Rashmi Sinha²², Nicolino Ruperto²³, Joost Swart²⁴, Bruno Fautrel²⁵, Sebastiaan Vastert¹ and Francesca Minoia²⁶, ¹University Medical Center Utrecht, Utrecht, Utrecht, Netherlands, ²ASST-Pini-CTO, Milano, Milan, Italy, ³IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Rome, Italy, ⁴University Hospital Muenster, Muenster, Germany, ⁵IRCCS G. Gaslini, Genova, Genoa, Italy, ⁶University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ⁷Hospital Sant Joan de Düu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁸UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰University of Alabama at Birmingham, Birmingham, AL, ¹¹Bambino Gesu Children's Hospital, Rome, Rome, Italy, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ¹⁴Karolinska University Hospital, Sollentuna, Sweden, ¹⁵SRCC Childrens Hospital Mumbai, Mumbai, India, ¹⁶Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan, Kobe, Japan, ¹⁷Hacettepe University Medical Faculty, Ankara, Turkey, ¹⁸Necker hospital, Paris Cedex ¹⁵, France, ¹⁹IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ²⁰Tokyo Medical and Dental University, Bunkyo-ku, Kanazawa, Japan, ²¹Childrens Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ²²Systemic JIA Foundation, Cincinnati, OH, ²³Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, ²⁴Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, ²⁵Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ²⁶Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy
Background/Purpose: The outcome of Still’s disease (SD) has significantly improved due to new therapeutic options [37923864], early biologic initiation [24623686] and treat-to-target strategies [39317417]. Nonetheless,…
Abstract Number: 1823 • ACR Convergence 2025
Genome-Wide DNA Methylation Analysis in Familial Mediterranean Fever
Kader Cetin Gedik¹, Desire Casares Marfil², Busra Baser Taskin³, Elif Kilic Konte⁴, Sezgin Sahin⁴, Mckenna Bowes², Ferhat Guzel⁵, Micol Romano⁶, Ozgur Kasapcopur⁷, Nuray Aktay Ayaz³, Erkan Demirkaya⁶ and Amr Sawalha², ¹UPMC Children's Hospital of Pittsburgh/University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Istanbul University Medical School, Istanbul, Turkey, ⁴Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ⁵Department of Research and Development, Ant Biotechnology, Istanbul, Turkey, ⁶University of Western Ontario, London, ON, Canada, ⁷Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey
Background/Purpose: Familial Mediterranean fever (FMF) is an autoinflammatory disease most commonly associated with biallelic mutations in the MEFV gene. Patients carrying the same pathogenic variant…
Abstract Number: 1706 • ACR Convergence 2025
Overcoming Barriers to ANA Testing in Pediatric Populations in Africa
Ekemini Ogbu¹, Angela Migowa², Rashmi Sahay¹, Dhriti Sharma¹, Patricia Vega-Fernandez¹, Michael Henrickson¹, Evans Omalla³, Ayodele Faleye⁴, Wafa Hamdi⁵ and Hermine Brunner¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Aga Khan University Medical College East Africa, Nairobi, Kenya, ³Pediatric Society of the African League Against Rheumatism, Nairobi, Kenya, ⁴Lagos state university teaching hospital Ikeja, Lagos, Lagos, Nigeria, ⁵Kassab Institute, Faculty of Medicine of Tunis UR¹⁷SP⁰⁴, Tunis El Manar Univeristy, MANOUBA, Tunisia
Background/Purpose: Timely diagnosis of children, adolescents and young adults with rheumatologic disorders remains a global challenge especially in lower resource countries and areas (LRCs). There…
Abstract Number: 1299 • ACR Convergence 2025
Pediatric Antiphospholipid Syndrome in a Large Tertiary Center
Rasha Elrefai, Marietta De Guzman, Jun Teruya, Vadim Kostousov, Amir Navaei and Olivia Kwan, Baylor College of Medicine, Houston, TX
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune condition defined as the presence of thrombotic events and/or pregnancy morbidity, accompanied by persistent antiphospholipid antibodies (aPLs). Pediatric…
Abstract Number: 1282 • ACR Convergence 2025
Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
Alina-Lucica Boteanu¹, Clara Udaondo², Joan Calzada³, Daniel Clemente Garulo⁴, Juan Carlos Nieto Gonzáles⁵, Eugenia Enriquez⁶, inmaculada Calvo Penades⁷, Lourdes Villalobos⁸, Belen Sevilla⁹, Sara Murias¹⁰, Berta Magallares¹¹, Ana Capilla¹², Jaime Arroyo¹³, Beatriz Bravo¹⁴, Gisela Diez-Cordoves¹⁵, Marisol Camacho¹⁶, Genaro grana¹⁷, Juan Jose Bethencourt¹⁸, Pablo Mesa¹⁹, Natalia Palmou²⁰, Mireia Lopez Corbeto²¹, Judith Sanchez²², Maria Isabel Gonzalez²³, isabel Patora Granados bautista²⁴, Clara Moriano²⁵, Diego Dios¹⁷, Lorena Exposito²⁶, Alicia Garcia²⁷, Laura Martin²⁸, David Fernandez²⁹, Laura Trujillo¹⁴, Anahy Maria Brandy³⁰ and CARLOS GUILLEN-ASTETE³¹, ¹H.U. Ramón y Cajal, Madrid, Spain, ²La Paz University Hospital, Madrid, Spain, ³University Hospital Sant Joan de Deu, Barcelona, Spain, ⁴H.U Niño Jesús, Madrid, Spain, ⁵H.U Gregorio Marañón, Madrid, Spain, ⁶Clínica Universidad de Navarra, Madrid, Spain, ⁷Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ⁸Ramon y Cajal Hospital, MADRID, Spain, ⁹Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁰H.U Central de Asturias, Oviedo, Spain, ¹¹Hospital de Sant Pau, Bareclona, ¹²H.U de La Merced, Sevilla, Spain, ¹³HOSPITAL UNIVERSITARIO LA PAZ, MADRID, ¹⁴H.U Virgen de Las Nieves, Granada, Spain, ¹⁵H. R. U. Malaga, Malaga, Spain, ¹⁶H.U. Virgen del Rocío, Sevilla, Spain, ¹⁷H.U de A Coruña, A Coruña, Spain, ¹⁸H.U. Canarias, Canarias, Spain, ¹⁹H.U Virgen de la Arrixaca, Murcia, Spain, ²⁰H.U. marques de Valdecilla, Santander, Spain, ²¹H.U Vall d´Hebron, Barcelona, Spain, ²²Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ²³H.U. La Fé, Valencia, Spain, ²⁴H.U Toledo, Toledo, Spain, ²⁵Hospital León, LEON, Castilla y Leon, Spain, ²⁶H.U Canarias, Canarias, Spain, ²⁷Rheumatologist, La Laguna, Spain, ²⁸H.R.U Malaga, Malaga, Spain, ²⁹Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ³⁰Hospital Germans Trias i Pujol, Badalona, Spain, ³¹H.U Ramón y Cajal, Madrid, Spain
Background/Purpose: SLE is a multisystemic autoimmune disease with several manifestations. Childhood-onset SLE (cSLE) has a more severe disease course than adult-onset SLE, with a higher…
Abstract Number: 0829 • ACR Convergence 2025
Multi-Center Use of an Online Case-Based Simulation to Evaluate Medical Trainee Use of Diagnostic Imaging and Lab Tests to Correctly Diagnose MSK Complaints
James McCarthey¹, Kyla Driest², erin frank¹, Allayne Stephans¹, Stacey Tarvin³ and Angela Robinson⁴, ¹Rainbow Babies and Children's Hospital, Cleveland, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Riley Hospital for Children at Indiana University, Indianapolis, IN, ⁴Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Our goal is to teach medical trainees high value care concepts and musculoskeletal (MSK) disease states and then implement online case-based simulations to evaluate…
Abstract Number: 0406 • ACR Convergence 2025
Comparing biomarkers associated with uveitis in tear fluid and serum samples of children with Juvenile Idiopathic Arthritis
Ilaria Maccora¹, Mariia Pavlenko², Mekibib Altaye³, Hermine Brunner⁴, Margaret Chang⁵, Ashley Cooper⁶, Stefanie Davidson⁷, Alexandra Duell⁴, Bharti Gangwani⁵, Aimee Hersh⁸, Gary Holland⁹, Carl Langefeld¹⁰, Melissa Lerman¹¹, Mindy Lo⁵, Virginia Miraldi Utz⁴, Sampath Prahalad¹², Grant Schulert⁴, Megan Quinlan-Waters¹³, Erin Stahl⁶, Edmund Tsui⁹ and Sheila Angeles-Han¹⁴, ¹Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, ²Rheumatology Division, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH, ³Cincinnati Children's Hospital, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Boston Children's Hospital, Boston, MA, ⁶Children's Mercy Kansas City, Kansas City, MO, ⁷Department of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Philadelphia, PA, ⁸University of Utah, Salt Lake City, UT, ⁹UCLA Jules Stein Eye Institute and the Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, ¹⁰Wake Forest University School of Medicine, Winston Salem, NC, ¹¹Children's Hospital of Philadelphia, Philadelphia, PA, ¹²Emory + Children's Pediatric Institute, Atlanta, GA, ¹³Cincinnati Children's Hospital Medical Center, CCHMC, ¹⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Chronic anterior uveitis (CAU) develops in 15-20% of juvenile idiopathic arthritis (JIA) cases. Early detection may prevent vision loss. However, known clinical risk factors…
Abstract Number: 0229 • ACR Convergence 2025
Leveraging the Electronic Medical Record to Improve the Rate of Discrete Data Collection in a Pediatric Rheumatology Clinic
Lisa Buckley¹ and Eli Lourie², ¹Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ²Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: A systematic approach to clinical data collection is critical to enhancing patient outcomes, enabling research and quality improvement initiatives, and benchmarking performance. This quality…

« Previous Page
1
…
6
7
8
9
10
…
62
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].